Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to tackle tough pancreatic cancer

NCT ID NCT06646055

Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, AK112 and cadonilimab, combined with standard chemotherapy as a first treatment for people with metastatic pancreatic cancer. About 110 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is to find a better option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AK112, cadonilimab, nab-paclitaxel, gemcitabine
What this could lead to
If successful, this combination could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 110 participants, so results may not apply broadly. The added drugs may increase side effects, and the treatment may not work better than standard chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). 2. ≥18 years old and ≤ 75 years (regardless of sex). 3. ECOG performance status 0-1 4. Life expectancy longer than 3 months. 5. Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal carcinoma (PDAC). 6. No prior systemic anti-tumor therapy for metastatic PDAC. 7. Adequate organ function. 8. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Exclusion Criteria: 1. Histological or cytological diagnosis of other pathological types. 2. BRCA1/2 or PALB2 mutations. 3. Participating in another clinical research. 4. Active central nervous system (CNS) metastases. 5. Undergoing systemic antiangiogenic therapy. 6. Acute or subacute pancreatitis. 7. Other known malignancies within five years. 8. Active infection requiring systemic therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.